Valeant Pharmaceuticals International's RELISTOR Tablets are now available for prescriptions in the United States to treat adults with chronic non-cancer pain who are experiencing opioid-induced constipation (OIC).
"We are very pleased to launch RELISTOR Tablets in the U.S. and provide an exceptional new treatment option for the millions of patients who suffer from extreme discomfort due to OIC," Valeant CEO Joseph C. Papa said. "This new method of delivery for RELISTOR offers healthcare professionals a novel alternative to address the treatment of OIC – a growing need in pain management – and demonstrates Valeant's continued commitment to delivering innovative products that improve people's lives."
RELISTOR Tablets were featured at U.S. PAINWeek this fall in Las Vegas. During the event, Miami Health System professor of pathology Dr. Steven Simon presented “Opioid-Induced Constipation When Reliable and Rapid Relief Matters."